Homogeneous Antibody-based FRET Immunoassays

Case ID: 00517



    This invention details use of the protein L binding domain as a convenient handle for converting off-the-shelf antibodies or fragments into a rapid, sensitive, single-step, homogeneous, and non-competitive immunoassay.  Protein L binds to all antibody classes including Fab fragments and single chain variable fragments.  This allows for direct detection without the need for multiple incubation or additional signal-generating elements and is faster and simpler than conventional Enzyme-Linked Immunosorbent Assays (ELISA).

Protein L (red) bound to the light chain

    (cyan) of a murine immunoglobulin.

Market Description
    The global immunoassay market is projected to be worth $25 billion by 2021 and the ELISA market alone is projected to reach $165 million.  ELISA kits in the US produced $75 million in sales in 2015. 


Key Advantages:

    •Simple protocols – Homogeneous, no washing

    •Broad dynamic range (4-5 orders of magnitude)

    •High sensitivities (fg/mL to pg/mL)

    •Small samples sizes (5 uL or less)

    •High throughput compatible

    •Cost effective       

Ideal For:

    •Novel targets and rare or proprietary biomarkers

    •Complex biofluids (plasma, serum, cell lysates, etc.)

    •Soluble and intracellular targets

    •Protein-protein interactions


Patent Status

    US Patent 7,741,128 B2, WO2008020823A2, etc.




Patent Information:
Wei-Wen (Winston) Su

For information, contact:
Ann Park
Technology Licensing Associate
University of Hawaii
(808) 956-9929

© 2018. All Rights Reserved. Powered by Inteum